Mechanistic definition of the cardiovascular mPGES-1/COX-2/ADMA axis

Nicholas S. Kirkby 1*†, Joan Raouf2†, Blerina Ahmetaj-Shala1†, Bin Liu 3, Sarah I. Mazi1,4, Matthew L. Edin5, Mark Geoffrey Chambers6, Marina Korotkova 2, Xiaomeng Wang7,8,9,10, Walter Wahli 7,11, Darryl C. Zeldin5, Rolf Nüsing12, Yingbi Zhou3, Per-Johan Jakobsson2,13‡, and Jane A. Mitchell1*‡

1National Heart & Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK; 2Unit of Rheumatology, Department of Medicine, Karolinska Institute, Stockholm, Sweden; 3Cardiovascular Research Centre, Shantou University Medical College, Shantou, China; 4King Fahad Cardiac Center, King Saud University, Riyadh, Saudi Arabia; 5National Institute for Environmental Health Sciences, Durham, NC, USA; 6Biotechnology and Autoimmunity Research, Eli Lilly and Company, Indianapolis, IN, USA; 7Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore; 8Institute of Molecular and Cell Biology, Agency for Science Technology & Research, Singapore, Singapore; 9Department of Cell Biology, Institute of Ophthalmology, University College London, London, UK; 10Singapore Eye Research Institute, Singapore, Singapore; 11Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland; 12Clinical Pharmacology and Pharmacotherapy Department, Goethe University, Frankfurt, Germany; and 13Karolinska University Hospital, Stockholm, Sweden

Received 9 October 2018; revised 23 May 2019; editorial decision 26 October 2019; accepted 31 October 2019; online publish-ahead-of-print 5 November 2019

Time for primary review: 41 days

Aims
Cardiovascular side effects caused by non-steroidal anti-inflammatory drugs (NSAIDs), which all inhibit cyclooxygenase (COX)-2, have prevented development of new drugs that target prostaglandins to treat inflammation and cancer. Microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors have efficacy in the NSAID arena but their cardiovascular safety is not known. Our previous work identified asymmetric dimethylarginine (ADMA), an inhibitor of endothelial nitric oxide synthase, as a potential biomarker of cardiovascular toxicity associated with blockade of COX-2. Here, we have used pharmacological tools and genetically modified mice to delineate mPGES-1 and COX-2 in the regulation of ADMA.

Methods and results
Inhibition of COX-2 but not mPGES-1 deletion resulted in increased plasma ADMA levels. mPGES-1 deletion but not COX-2 inhibition resulted in increased plasma prostacyclin levels. These differences were explained by distinct compartmentalization of COX-2 and mPGES-1 in the kidney. Data from prostanoid synthase/receptor knockout mice showed that the COX-2/ADMA axis is controlled by prostacyclin receptors (IP and PPARβ/δ) and the inhibitory PGE2 receptor EP4, but not other PGE2 receptors.

Conclusion
These data demonstrate that inhibition of mPGES-1 spares the renal COX-2/ADMA pathway and define mechanistically how COX-2 regulates ADMA.
1. Introduction

Cyclooxygenase (COX) is a ubiquitous checkpoint in cardiovascular homeostasis and is present in two forms, COX-1 and COX-2. COX-1 is constitutively expressed throughout the body, including in platelets and endothelial cells, whilst COX-2 is restricted to specific regions which include the kidney where it is present in numerous cell types including fibroblasts, tubular epithelial cells, and endothelial cells. COX-1 in platelets drives prothrombotic thromboxane and is the therapeutic target of low-dose aspirin. In contrast, constitutively expressed COX-2 protects the cardiovascular system. We know this because mice lacking COX-2 are prone to atherosclerosis, thrombosis, and hypertension, and because the non-steroidal anti-inflammatory drugs (NSAIDs) class of drugs, which all work by blocking COX-2-derived prostaglandin (PG)E2 and other prostanooids at the site of inflammation, cause much reported cardiovascular side effects. These side effects are associated with all members of the NSAID class except aspirin and increase personal risk of having a heart attack or stroke by as much as 30% even after only 2 weeks of regular use. Importantly, they amount to a global problem because NSAIDs are amongst the most commonly used pain medications worldwide and can prevent cancer. However, the precise mechanism(s) by which NSAIDs cause cardiovascular side effects are not completely understood causing serious consequences including that (i) there are no means of identifying patients at risk, (ii) NSAIDs are not used to prevent cancer, and (iii) the development of new drugs that target prostanoids has declined.

What we do know is that inhibition of protective prostanoids, particularly prostacyclin or PG\textsubscript{E2}, derived from constitutively expressed COX-2 in the kidney or at other sites, underpins cardiovascular toxicity of NSAIDs. With this in mind, selective drug targeting of PG\textsubscript{E2}...
at the site of inflammation may well provide a therapeutic strategy to
treat disease whilst sparing the release of cardioprotective prosta-
noids. This could be achieved by inhibition of microsomal prostaglan-
din (PG) E synthase-1 (mPGES-1), a prostaglandin synthase, which
converts intermediates produced by COX-1 and COX-2 to proinflam-
atory PGE2.25 Inhibition of mPGES-1 is a well-developed area of pre-
clinical research with studies showing that its genetic deletion protects
against inflammation, pain and cancer;26–28 however, clinical develop-
ment of mPGES-1 as a therapeutic target has been stopped. In some
cases, this has been for specific reasons such as liver toxicity associ-
ated with LY3023703,29 but overall reflects a lack of a complete un-
derstanding surrounding NSAID cardiovascular toxicity and of relevant
biomarkers.

Most recently work from our group8 and others19 has shown a link
between inhibition of COX-2 and the endothelial nitric oxide synthase
(eNOS) pathway which helps to explain how COX-2 protects the car-
diovascular system. Our work additionally implicates the naturally occur-
rning eNOS inhibitors asymmetric dimethylarginine (ADMA)30 and/or
monomethylarginine (LNMMA)31 as biomarkers and mechanistic explan-
ations of how loss of COX-2 mediates vascular dysfunction. ADMA is an
established cardiovascular biomarker in both preclinical and clinical stud-
ies.30 However, the precise role of prostacyclin synthase (PGIS),
mPGES-1, and associated downstream receptor signalling in the COX-2/
ADMA axis is not known.

Thus, in the current study, we have used pharmacological tools and a
full range of genetically modified mice to determine the precise involve-
ment of COX-2, mPGES-1, PGIS, and respective prostanoid signalling
receptors in the regulation of ADMA. This work validates and explains
the ‘COX-2-ADMA axis’ and suggests an empirical estimation of the rel-
ative cardiovascular safety of mPGES-1 and COX-2 as therapeutic tar-
gets in man.

2. Methods

2.1 Animals

Male and female, 6- to 8-week-old wild-type mice, or mice lacking
mPGES-1.31 PGIS (newly generated, see below), IP,32 PPARd/3,33
EP3,34 EP2,35 EP3,36 EP4,37 or DP138 were used. Animals were housed
in individually ventilated cages, with 12 h day/night cycle and free ac-
cess to standard mouse chow and water. Studies were performed
across multiple institutes, however in each case, (i) wherever possible
samples were collected and data analysed by investigators blinded to
the genotype/treatment of the animals, (ii) the same investigators col-
collected and analysed tissue in all studies, (iii) tissue from relevant con-
trol animals was collected at the same time from the same source, and
(iv) experiments were performed in accordance with all local guide-
lines, legislation and after ethical review and the Animals (Scientific
Procedures) Act (1986) Amendment (2013). Experiments on
mPGES-1-/- mice, PGIS-/- mice, and PPAR

2.2 Generation of PGIS-/- mice

PGIS-/- mice were generated by Beijing View Solid Biotechnology (Beijing, China) using transcription activator-like effector nucleosome
(TALEN).39 TALEN constructs targeting exon 2 of the PGIS locus were
designed by using TAL Effector Nucleotide Targeter 2.0 (https://tale-nt.
cac.cornell.edu/ node/add/talen). The target sequences were: left 5'-
GAGCCTCCCCGTAGACCT-3' and right 5'-CCAAGGGATGGCCAGC
AGC-3'. All constructs were validated by DNA sequencing. TALEN
mRNA was injected into mouse (C57BL/6) zygotes which were then
transferred to pseudopregnant females to generate mutant founders
(F0). Founders carrying frameshift mutations were intercrossed with
wild-type mice to produce the F1 generation. PCR was performed with
tail clip DNA from weaned mice with the primers: 5'-CAGCCTA
CTCTGACTTCCCCATG-3' and 5'-GGGTGAGTGAAGGCA
TTAACTC-3' for sense and antisense primers respectively. Mice were gen-
typed by sequencing the PCR products. The T7E1 (Beijing View Solid
Biotechnology) assay was used to validate targeting efficiency and screen
for the desired mutant mice. F1 mice with deletion of 14 bp
(GCACATCCCCCTGG) in exon 2 of the Ptgis locus were bred to pro-
duce PGIS-/- mice.

2.3 Circulating mediators

Mice were killed by CO2 narcosis, blood collected from the inferior
vena cava into heparin (10 U/mL final; Leo Laboratories, UK) and plasma
separated. Levels of ADMA and arginine (DLD Diagnostika, Germany),
the prostacyclin break-down product, 6-keto-PGF1α (Cayman Chemical,
USA), or creatinine (Cayman Chemical, USA) were measured by com-
mercial biochemical/immunoassay kit.

2.4 Prostanoid release and measurement

Prostanoid release ex vivo was measured as we have previously de-
scribed.36 Briefly, segments of renal medulla, renal cortex or aorta were
incubated in DMEM media (Sigma, UK) containing Ca2+ ionophore
A23187 (30 μmol/L; Sigma, UK) for 30 min at 37°C then release of PGE2
6-keto-PGF1α was measured by immunoassay (Cisbio, France and
Cayman Chemical, USA, respectively). In some cases, levels of a panel of
eicosanoids was measured in the supernatant using an LC/MS/MS plat-
form as previously described.40

2.5 Gene and protein expression

RNA was isolated from renal medulla and gene expression determined
using TaqMan hydrolysis probes (Life Technologies, UK). Data were nor-
malized to expression of the housekeeping genes 18S (probe ID:
Mm03928990_g1) and Gapdh (probe ID: Mm99999915_g1) and relative
expression compared using the comparative Ct method. Protein was isolated by homogenizing frozen tissue in PBS containing a protease inhibitor cocktail (Roche Bioscience, UK). mPGES-1 protein levels were measured using a specific ELISA (Mybiosource, USA) and normalized to total protein levels determined using the bicinchoninic acid method (Thermo Fisher Scientific, UK).

2.6 Statistics and data analysis
Data were analysed using Prism 7.0 software (Graphpad software, USA) and are presented as mean ± standard error for ’n’ number of animals. N values for individual studies are given in figure legends. The experimental design for the primary endpoint of the study (plasma ADMA levels in mice where mPGES-1 was deleted or COX-2 was inhibited; Figure 1A) was based on formal power calculations. Effect size and variance were estimated from our previously published data on plasma ADMA in mice treated with parecoxib8 (Cohen’s D = 1.67) such that n = 7 provided 81% power by detect a significant difference (P < 0.05; two-tailed) in a three-group comparison. Subsequent mechanistic experiments were not the subject of formal power calculations. Differences were considered significant if P < 0.05. Details of statistical tests applied are given in each figure legend.

3. Results and discussion
3.1 Differential effects of mPGES-1 and COX-2 inhibition on plasma ADMA and prostacyclin
Two biomarkers have emerged as candidates to assess and predict the cardiovascular toxicity of anti-inflammatory drugs targeting COX-2 and/or the prostaglandin cascade. The first of these is prostacyclin, which is well established as a cardinal cardiovascular protective mediator derived from the COX pathway. Metabolites of prostacyclin can be measured in the urine, but these can be produced in the kidney and do not necessarily reflect prostacyclin production in the circulation.4,42,43 Instead, the prostacyclin breakdown product 6-keto-PGF1α can be measured in the plasma, levels of which do correlate with prostacyclin production by systemic blood vessels.4,44 The second is ADMA, an established predictor of cardiovascular risk in the general population.3,45 Although to date no clinical data are available for the association between ADMA levels and cardiovascular risk in NSAID users, plasma ADMA is increased in COX-2 knockout mice with no associated change in plasma prostacyclin.8 Here, we show that ADMA is similarly increased plasma of wild-type mice where COX-2 is inhibited pharmacologically with chronic dosing (5 days) of parecoxib (Figure 1A). As with genetic deletion,4 COX-2 inhibition with parecoxib did not affect plasma levels of prostacyclin (Figure 1B). In contrast, loss of mPGES-1 had no effect on plasma ADMA but increased plasma prostacyclin (Figure 1A and B). We have previously shown that the increase in ADMA seen in COX-2 knockout mice is associated with renal dysfunction and mediated by changes in methylarginine-processing enzymes in the kidney.8 This point was recently corroborated in studies showing that ADMA was not increased and methylarginine genes not altered in models of reduced COX-2 that spare the kidney.46 In the current study plasma creatinine, a standard marker for predicting renal impairment, was increased in mice treated with parecoxib (Figure 2A) but unaffected in mPGES-1 knockout mice (Figure 2A). In line with this parecoxib increased expression of the gene encoding the ADMA synthetic enzyme Prmt1 (Pmr1; Figure 2B) and reduced expression of the gene encoding the ADMA metabolizing enzyme Agxt2 (Agxt2; Figure 2C). In contrast, deletion of mPGES-1 had no effect on Pmr1 or Agxt2 expression (Figure 2), which explains the lack of change in circulating ADMA levels (Figure 2E). Neither parecoxib treatment nor mPGES-1 deletion influenced expression of the gene encoding the alternative ADMA metabolic enzyme Ddah1 (Ddah1; Figure 2D). These observations suggest that, in direct contrast to COX-2 inhibition, targeting mPGES-1 spares both general renal function and the protective effects of renal COX-2 on the ADMA pathway. These findings agree with reports that mPGES-1 has a minimal role in the regulation of blood pressure and salt/water handling by the kidney in animal models47 and that in human healthy volunteers small, sporadic changes in plasma creatinine levels are not associated with changes in glomerular filtration rate or blood pressure.48 This further corroborates the idea that unlike COX-2, mPGES-1 does not play a substantial role in controlling cardio-renal physiology.49

With the data above demonstrating that mPGES-1 inhibition spares the renal COX-2/methylarginine pathway and boosts circulating prostacyclin levels, we went on to use these models to perform mechanistic investigations. We addressed the two underlying questions: (i) how and why do mPGES-1 inhibitors spare the COX-2/ADMA axis and (ii) how
does mPGES-1 blockade boost vascular prostacyclin production? These are considered in turn below.

3.2 How does mPGES-1 blockade spare the COX-2/ADMA axis?

There are two possible scenarios that explain why loss of mPGES-1 does not result in increased ADMA. Scenario 1: PGE2 signalling does not regulate ADMA. Scenario 2: PGE2 does regulate ADMA but that mPGES-1 is not involved in PGE2 formation at the site where methylarginines are processed. To address scenario 1, we used a range of genetically modified mice where individual prostanoid genes were deleted and measured plasma levels of ADMA.

The role of PGE2 in the COX-2/ADMA axis has not been explored but there is evidence that implicates prostacyclin since we have previously reported that mice lacking the classical prostacyclin receptor, IP, have elevated plasma ADMA. However, in that study comparisons with other prostanoid pathways, including PGE2, were not made. Since prostacyclin may signal through other non-IP, prostanoid receptors, as well as nuclear receptors of the PPAR family, to fully evaluate the role of prostacyclin in controlling the renal ADMA axis, we generated a novel PGIS knockout mouse line where endogenous prostacyclin is completely removed and confirmed the predicted phenotype by measuring plasma 6-keto-PGF1α. Deletion of PGIS was associated with an almost complete loss of plasma prostacyclin (PGISKO: 400.6 ± 106.1 pg/mL; PGIS+/−, 29.0 ± 5.8 pg/mL; P = 0.002) and increased plasma ADMA (Figure 3A) to a similar degree as seen in mice treated with parecoxib (Figure 1E). To determine the signalling pathways downstream of prostacyclin generation responsible for ADMA regulation we studied mice lacking IP and PPARβ/δ. Deletion of either IP (Figure 3B) or PPARβ/δ (Figure 3C) resulted in elevation of plasma ADMA levels. However, deletion of the prostaglandin D2 receptor DP1, which can also be activated by prostacyclin and shares similar signalling to IP, had no effect on plasma ADMA levels (Figure 3D).

These data are entirely consistent with the idea that COX-2-derived prostacyclin production regulates ADMA levels but doesn’t however, rule out a similar or complementary functional role for COX-2/mPGES-1-derived PGE2. To address this possibility we studied ADMA levels in the plasma of a full range of PGE2 receptor knockout mice. PGE2 utilizes four classical receptors, EP1-4, each linked to distinct signalling cascades, with EP4 being associated with cardioprotective properties including vasodilation and inhibition of platelet aggregation. Plasma ADMA was unaffected by deletion of EP1, EP2 or EP3 (Figure 3E). However, plasma ADMA was increased in EP4 knockout mice (Figure 3E). These observations suggest that both prostacyclin and PGE2 exert breaks on plasma ADMA and thereby rule out scenario 1 as an explanation for why mPGES-1 blockade spares ADMA.

This leaves us with scenario 2; that mPGES-1 does not drive the ‘protective’ PGE2 which limits ADMA levels in vivo. We know that constitutive COX-2 and methylarginine pathways are co-localized specifically within the renal medulla and that here, rather than the cortex, or another site, is where NSAIDs act to increase ADMA. We know that both mPGES-1 and COX-2 are constitutively expressed in the kidney and that deletion of either gene reduces urinary markers of PGE2. Thus, to address scenario 2 we measured mPGES-1 expression and activity in the renal medulla and renal cortex. mPGES-1 was expressed at significantly higher levels in the renal cortex compared to the renal medulla at both the mRNA (Figure 4A) and protein level (Figure 4B) whilst, as we
have previously shown, COX-2 was expressed almost exclusively within the renal medulla (Figure 4C). In line with this PGE2 levels in cortex from mPGES-1 knock out mice were reduced (Figure 4D) whilst levels in renal medulla were unchanged (Figure 4E). Levels of prostacyclin production by the renal cortex (wild type: 6.2 ± 0.7 ng/mL; mPGES-1 -/-: 5.8 ± 1.1; \( P = 0.80; n = 5 \)) or renal medulla (wild type: 14.2 ± 2.8 ng/mL; mPGES-1 -/-: 19.2 ± 1.3; \( P = 0.13; n = 5 \)) were not altered by deletion of mPGES-1 consistent with a specific effect on renal cortical PGE2 production. These observations show that mPGES-1 and COX-2 are oppositely compartmentalized within the kidney and explain why, despite PGE2 (via EP4) regulating ADMA, inhibiting mPGES-1 spares renal methylarginine processing. Although it would be advantageous to confirm this in human tissue such as biopsy material or cultured cells/organoids, such studies are limited by the rapid induction of COX-2 and mPGES-1 ex vivo.

### 3.3 How does mPGES-1 regulate prostacyclin production in vessels?

We next separately addressed the link between mPGES-1 deletion and vascular prostacyclin. The finding that deletion of mPGES-1 increases plasma prostacyclin is likely to reflect the well-recognized phenomenon that excess PGH2 substrate can be diverted between prostanoid synthetic pathways. This is in agreement with previous reports that urinary prostacyclin metabolites are increased in healthy volunteers receiving the mPGES-1 inhibitor, LY3023703. However, which tissues or cellular sites are involved in the shunting of PGH2 from mPGES-1 \( \Rightarrow \) PGIS are not known but important to consider since any drug which increases vascular prostacyclin has the potential to protect the cardiovascular system.

To understand the role that vascular PGIS plays in the shunting away from PGE2 towards prostacyclin when mPGES-1 is blocked we studied isolated aorta from wild-type and knockout mice. In blood vessels, studied immediately post-mortem to exclude any possibility of artefactual enzyme induction, prostacyclin (6-ketoPGF1\(_\alpha\)) was by far the most abundant prostanoid released, with levels /C24 10 times higher than PGE2 (Figure 5). These observations are entirely consistent with what we know of vascular prostacyclin and PGE2 production. Nevertheless, release of PGE2 from freshly isolated aortic rings was reduced by mPGES-1 deletion (Figure 5A), suggesting mPGES-1 is constitutively expressed in large vessels where it contributes to physiological PGE2 production. However, we did not detect any concomitant increase in prostacyclin associated with reduced PGE2 production in the aorta (Figure 5B). Amongst other eicosanoids measured 12-HETE, 9-HODE, and 13-HODE dominated but were, as with prostacyclin, unaffected by mPGES-1 deletion (Figure 5C). These observations show that PGIS is expressed in excess in large blood vessels and that in this setting; the diversion of a small amount of PGH2 substrate from mPGES-1 does not impact on total prostacyclin levels within the vasculature. Our vascular results are limited to studies of the mouse aorta, however, together these observations suggest that mPGES-1 \( \Rightarrow \) PGIS shunting occurs in
**Figure 4** mPGES-1 and COX-2 have distinct compartmentalization within the kidney. Expression of mPGES-1 (Ptges) at mRNA level by qPCR (A) and protein level by ELISA (B) in renal cortex and medulla of wild-type mice. mRNA expression of COX-2 (Ptgs2) by qPCR in the renal cortex and renal medulla of wild-type mice (C). PGE₂ production by isolated segments of renal cortex (D) and medulla (E) from wild-type and mPGES-1 knockout (KO) mice. Data are mean ± S.E.M. for n = 5–8 mice in each group. *P < 0.05 by unpaired t-test.

**Figure 5** mPGES-1 contributes to constitutive vascular PGE₂ production but its deletion does not increase local production of prostacyclin or other eicosanoids. Release of PGE₂ (A) and 6-keto-PGF₁α (stable breakdown product of prostacyclin) (B) and a full range of eicosanoids (C) by isolated aortic rings from wild-type and mPGES-1 knockout (KO) mice. For panel (C) only detectable eicosanoids are shown. The following mediators were assayed but were below limits of detection: PGH₂, 8-iso-PGF₂α, 8-iso-PGF₁α, 15-iso-PGE₂, 20-OH-PGF₂α, LTC₄, LTD₄, 20-carboxy-LTB₄, 8-HETE, 19-HETE, 20-HETE, 20-HEPE, 11,12-EET, 8,9-EET, 17,18-DHET, 19,20-EpDPE, 12,13-EpOME, 12,13-DHOME, 9,10-DHOME, 19,20-DiHDPA, 17,18-EpETE, 22-HDoHE, AA, LA, 20-carboxy-AA. Data are mean ± S.E.M. (A, B): *P < 0.05 by (A, B) unpaired t-test for n = 5–7 mice per group. (C) Unpaired t-test with Benjamini–Hochberg FDR correction for n = 4 mice per group.
localized vascular beds or extra-vascular sites, the location of which remains the subject of investigation. Similarly, the potential for increased prostacyclin at those locations within the body to protect the cardiovascular (or other) systems has yet to be determined.

4. Conclusion

Our data show that in mouse models blocking mPGES-1 spares the COX-2/ADMA axis whilst increasing plasma prostacyclin levels. Further, mechanistic studies using mouse models suggest this can be explained by distinct compartmentalization of COX-2 and mPGES-1 in the kidney and the role of specific prostacyclin-sensitive receptors (IP, PPARd and EP4) in renal ADMA handling. However, prostanoid renal physiology and pharmacology can differ between species and validating our murine work in human tissue studies remains the subject of investigation. Nonetheless, this work reveals the downstream mechanisms that underpin the COX-2/ADMA axis (summarized in the graphical abstract) and emphasize the potential importance and added value of ADMA as a biomarker approach to assessing the cardiovascular safety of drugs that target the prostaglandin cascade.

Authors' contributions

Conceived/design work (N.S.K., P.J.J., J.A.M.). Acquired/analysed/interpreted data (N.S.K., J.R., B.A., S.I.M., M.L.E., J.A.M.). Drafted manuscript (N.S.K., P.J.J., J.A.M.). Provided essential research tools/samples (B.L., M.L.E., M.G.C., X.W., W.W., D.C.Z., R.N., Y.Z.). Reviewed manuscript (N.S.K., J.R., B.A., S.I.M., M.L.E., M.G.C., X.W., W.W., D.C.Z., R.N., Y.Z., P.J.J., J.A.M.).

Acknowledgements

The authors thank Hime Gashaw and Fred Lih for technical assistance and Kelvin Jia Peng Chen, Yan Zhuang, Xuan Rui NG, Chenghao Liu, and Ming Keat SNG for providing Pparδ−/− mice and related expertise.

Conflict of interest: P-J.J. is a board member for Gesynta Pharma and -/- mice and related expertise. P-J.J. also holds patents related to mPGES-1 inhibition. J.A.M. has ongoing mPGES-1 inhibitor drugs for the treatment of inflammatory diseases. M.G.C is an employee of Eli Lilly and Company, both of which are developing mPGES-1 inhibitors.

References

1. Mitchell JA, Kirby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol 2016;176:1038–1050.
2. Klein T, Nusing RM, Pletschacher J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994;48:1605–1610.
3. Mitchell JA, Akarsureseont P, Thienerrmann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693–11697.
4. Kirby NS, Lundberg MH, Harrington LS, Leadbetter PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA 2012;109:17597–17602.
5. Mitchell JA, Lucas R, Vojinovic I, Hasan K, Pepper JR, Warner TD. Stronger inhibition by nonsteroidal anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J 2006;20:2468–2475.
6. Kirby NS, Zais AK, Urquhart P, Jao A, Austin PJ, Al-Yamani M, Lundberg MH, MacKenzie LS, Warner TD, Nicolau A, Herschman HR, Mitchell JA. LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS One 2013;8:e69524.
7. Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1999;277:F460–F468.
8. Ahmetaj-Shala B, Kirby NS, Knowles R, Al-Yamani M, Mazi S, Wang Z, Tucker AT, Mackenzie L, Armstrong PCJ, Nusing RM, Tomlinson JAP, Warner TD, Leiper J, Mitchell JA. Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation 2015;131:633–642.
9. Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol 2006;47(Suppl. 1):537–542.
10. Crescende M, Armstrong PC, Chan MV, Edin ML, Lih FB, Jao A, Gaston-Massuet C, Cottrell GS, Kirby NS, Mitchell JA, Zeldin DC, Herschman HR, Warner TD. Platelet COX-1 knockout mouse as a model of the effects of aspirin in the cardiovascular system. Heart 2017;103:A1083.
11. Schror K. Why we should not skip aspirin in cardiovascular prevention. Hamostaseologie 2016;36:33–43.
12. Gitlin JM, Loftin CD. Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice. Cardiovasc Res 2008;80:400–407.
13. Kirby NS, Lundberg MH, Wright WR, Warner TD, Paul-Clark MJ, Mitchell JA. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2-associated pathological pathways implicating PGI1 and lymphocyte net-works. PLoS One 2014;9:e88165.
14. Narasimha A, Watanabe J, Lin JA, Ha M, Langenbach R, Navab M, Fogelman AM, Reddy ST. A novel anti-atherogenic role for COX-2—potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins Other Lipid Mediat 2007;84:24–33.
15. Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, Ogumuwokina J, Epstein SE. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytokemeglovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol 2003;41:1812–1819.
16. Yu Z, Crichton I, Tang SY, Hui Y, Ricciotti E, Levin MD, Lawson JA, Pure E, Fitz Gerald GA. Disruption of the 5-lipoxygenase pathway attenuates atherosclerosis consequent to COX-2 deletion in mice. Proc Natl Acad Sci USA 2012;109:6727–6732.
17. Barbieri SS, Amadio P, Gianelli S, Tarantino E, Zacchi E, Veglia F, Howe LR, Weiskier BB, Mussoni L, Tremoli E. Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner. Circulation 2012;126:1373–1384.
18. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006;116:1391–1399.
19. Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I, Wu W, Pure E, Funk CD, Fitzgerald GA. Vascular COX-2 mediates blood pressure and thrombosis in mice. Sci Trans Med 2012;4:132rr54.
20. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhalia N, Emberson J, Merhi A, Bramssson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, Fitzgerald GA, Goss P, Hills H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schmitzer TJ, Solomon S, Tugwell P, Wilson K, Wissel J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769–779.
Non-steroidal anti-inflammatory drugs (NSAIDs) treat pain and inflammation and can prevent cancer but cause serious cardiovascular side effects resulting in the virtual arrest in development of drugs which target prostanoid pathways. This includes new cyclooxygenase (COX)-2 blockers and inhibitors of microsomal prostaglandin E synthase-1 (mPGES-1). Our work has indicated that the well-established cardiotoxic biomarker, asymmetric dimethylarginine (ADMA), is increased when COX-2 is lost. In this study, we reveal the downstream signalling pathways responsible for the protective break that COX-2 exerts on ADMA and that this is independent of the mPGES-1 pathway. Together these studies, support the idea that ADMA has utility as a biomarker and that in this setting mPGES-1 inhibitors spare the pathways associated with NSAID cardiovascular toxicity.